The RiskReveal assay was used to determine which early-stage non-squamous NSCLC patients should undergo adjuvant chemotherapy.

NEW YORK — Genedrive said Friday that it has received CE marking under the EU's In Vitro Diagnostic Medical Device Regulation (IVDR) for its point-of-care CYP2C19 ID Kit genotyping platform, which is ...

NEW YORK – Cizzle Bio, a London-based provider of blood tests for the early detection of lung and gastric cancers, this week inked an agreement with Doctors Hospital in the Cayman Islands to provide ...

The firm touted new assays, provided an update on its nanopore sequencer, and offered insights into upcoming pipeline ...

NEW YORK – OncoHost, an Israeli biotechnology company, is working with three European medical centers to produce a new flow cytometry test to predict patient response to immunotherapies for five ...

NEW YORK – Danaher announced Thursday that it is partnering with AstraZeneca to develop and commercialize novel diagnostic tests for precision medicine patients. Financial and other terms of the deal ...

NEW YORK – Precision oncology firm Predicta Biosciences last month took the first step in the product commercialization process by launching its whole-genome sequencing-based GenoPredicta assay for ...

Investors and consultants in the space said that they have seen rising enthusiasm among investors as recent funding rounds ...

The team developed a tumor-independent test that is used to evaluate genome-wide cell-free DNA fragmentation profiles and repeat landscapes.